Pfizer Company Profile (NYSE:PFE)

About Pfizer

Pfizer logoPfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel. Its commercial operations consist of two businesses: Innovative Products business and Established Products business. The Innovative Products business consists of two segments: the Global Innovative Pharmaceutical segment (GIP) and the Global Vaccines, Oncology and Consumer Healthcare segment (VOC). The Established Products business consists of the Global Established Pharmaceutical segment (GEP). Its research focuses on six areas, which include immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, and rare diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: PFE
  • CUSIP: 71708110
Key Metrics:
  • Previous Close: $32.40
  • 50 Day Moving Average: $33.57
  • 200 Day Moving Average: $34.38
  • 52-Week Range: $28.25 - $37.39
  • Trailing P/E Ratio: 28.72
  • Foreward P/E Ratio: 12.09
  • P/E Growth: 2.12
  • Market Cap: $196.53B
  • Outstanding Shares: 6,065,652,000
  • Beta: 0.86
  • Net Margins: 14.88%
  • Return on Equity: 23.37%
  • Return on Assets: 8.99%
  • Debt-to-Equity Ratio: 0.48%
  • Current Ratio: 1.37%
  • Quick Ratio: 1.13%
Additional Links:
Companies Related to Pfizer:

Analyst Ratings

Consensus Ratings for Pfizer (NYSE:PFE) (?)
Ratings Breakdown: 10 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $38.62 (19.21% upside)

Analysts' Ratings History for Pfizer (NYSE:PFE)
DateFirmActionRatingPrice TargetDetails
10/19/2016Sanford C. BernsteinSet Price TargetBuy$36.00View Rating Details
10/18/2016BMO Capital MarketsReiterated RatingOutperform$40.00View Rating Details
10/13/2016Jefferies GroupDowngradeBuy -> Hold$39.00 -> $36.00View Rating Details
10/4/2016ArgusReiterated RatingBuy$39.00View Rating Details
9/27/2016Bank of America Corp.Reiterated RatingBuy$40.00View Rating Details
8/23/2016Piper Jaffray Cos.Set Price TargetBuy$54.00View Rating Details
8/22/2016Credit Suisse Group AGReiterated RatingOutperform$40.00View Rating Details
8/18/2016Deutsche Bank AGReiterated RatingBuy$44.00View Rating Details
8/3/2016JPMorgan Chase & Co.Set Price TargetBuy$40.00View Rating Details
8/3/2016Citigroup Inc.Reiterated RatingNeutral$37.00View Rating Details
8/2/2016Barclays PLCReiterated RatingEqual Weight$34.00View Rating Details
5/17/2016Morgan StanleyReiterated RatingHold$36.00View Rating Details
5/12/2016Berenberg BankInitiated CoverageHold$38.00View Rating Details
5/9/2016Goldman Sachs Group Inc.Set Price TargetNeutral$37.00View Rating Details
5/4/2016Independent Research GmbHSet Price TargetNeutral$37.00View Rating Details
5/4/2016Societe GeneraleSet Price TargetNeutral$34.00View Rating Details
5/2/2016Leerink SwannLower Price TargetMarket Perform$37.00 -> $34.70View Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyView Rating Details
2/16/2016SunTrust Banks Inc.Lower Price TargetNeutral$37.00 -> $33.00View Rating Details
1/26/2016Nord/LBReiterated RatingBuyView Rating Details
1/5/2016Atlantic SecuritiesReiterated RatingBuy$39.00View Rating Details
12/2/2015Cowen and CompanyReiterated RatingBuy$43.00View Rating Details
11/24/2015Evercore ISIReiterated RatingBuy$38.00View Rating Details
(Data available from 10/27/2014 forward)


Earnings History for Pfizer (NYSE:PFE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2016Q216$0.62$0.64$13.01 billion$13.10 billionViewN/AView Earnings Details
5/3/2016Q116$0.55$0.67$12.00 billion$13.00 billionViewN/AView Earnings Details
2/2/2016Q415$0.52$0.53$13.57 billion$14.05 billionViewN/AView Earnings Details
10/27/2015Q315$0.51$0.60$11.56 billion$12.10 billionViewListenView Earnings Details
7/28/2015Q215$0.52$0.56$11.39 billion$11.00 billionViewListenView Earnings Details
4/28/2015Q115$0.49$0.51$10.79 billion$10.86 billionViewN/AView Earnings Details
1/27/2015Q414$0.53$0.54$12.94 billion$13.10 billionViewN/AView Earnings Details
10/28/2014Q314$0.55$0.57$12.24 billion$12.40 billionViewN/AView Earnings Details
7/29/2014Q214$0.57$0.58$12.49 billion$12.80 billionViewN/AView Earnings Details
5/5/2014Q114$0.56$0.57$12.07 billion$11.35 millionViewN/AView Earnings Details
1/27/2014Q413$0.52$0.56$13.35 billion$13.56 billionViewN/AView Earnings Details
10/29/2013Q313$0.56$0.58$12.69 billion$12.64 billionViewN/AView Earnings Details
7/30/2013Q2 2013$0.55$0.56$13.02 billion$12.97 billionViewListenView Earnings Details
4/30/2013Q1 2013$0.55$0.54$14.10 billion$13.50 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.44$0.47$14.40 billion$15.10 billionViewListenView Earnings Details
11/1/2012Q312$0.53$0.53$14.64 billion$14.00 billionViewN/AView Earnings Details
7/31/2012$0.54$0.62ViewN/AView Earnings Details
5/1/2012$0.57$0.58ViewN/AView Earnings Details
1/31/2012$0.47$0.50ViewN/AView Earnings Details
11/1/2011$0.55$0.62ViewN/AView Earnings Details
8/2/2011$0.59$0.60ViewN/AView Earnings Details
5/3/2011$0.59$0.60ViewN/AView Earnings Details
2/1/2011$0.46$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pfizer (NYSE:PFE)
Current Year EPS Consensus Estimate: $2.46 EPS
Next Year EPS Consensus Estimate: $2.68 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.54$0.56$0.55
Q2 20164$0.56$0.63$0.61
Q3 20163$0.61$0.63$0.62
Q4 20162$0.54$0.56$0.55
(Data provided by Zacks Investment Research)


Current Dividend Information for Pfizer (NYSE:PFE)
Annual Dividend:$1.20
Dividend Yield:3.70%
Dividend Growth:8.40% (3 Year Average)
Payout Ratio:95.24% (Based on Trailing 12 Months of Earnings)
48.78% (Based on Current Year Consensus EPS Estimate)
44.78% (Based on Next Year Consensus EPS Estimate)
Track Record:6 Years of Consecutive Dividend Growth

Dividend History for Pfizer (NYSE:PFE)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Pfizer (NYSE:PFE)
Insider Ownership Percentage: 0.07%
Institutional Ownership Percentage: 69.70%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/26/2016Frank A DamelioEVPSell100,000$34.49$3,449,000.00View SEC Filing  
5/24/2016Loretta V CangialosiVPSell86,000$33.97$2,921,420.00View SEC Filing  
5/11/2016Laurie J OlsonEVPSell4,700$33.50$157,450.00View SEC Filing  
5/10/2016Frank A DamelioEVPSell192,000$33.66$6,462,720.00View SEC Filing  
5/10/2016John D YoungInsiderSell41,700$33.53$1,398,201.00View SEC Filing  
5/9/2016Anthony J MaddalunaEVPSell8,950$33.75$302,062.50View SEC Filing  
5/9/2016Ian C ReadCEOSell275,000$33.80$9,295,000.00View SEC Filing  
5/5/2016Sally SusmanEVPSell76,116$33.75$2,568,915.00View SEC Filing  
5/4/2016Douglas M LanklerEVPSell29,700$33.69$1,000,593.00View SEC Filing  
5/4/2016Mikael DolstenInsiderSell67,588$33.46$2,261,494.48View SEC Filing  
5/3/2016Frank A DamelioEVPSell87,079$33.65$2,930,208.35View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.00View SEC Filing  
6/11/2015Laurie J OlsonEVPSell26,000$34.39$894,140.00View SEC Filing  
3/12/2015Sally SusmanEVPSell46,179$34.00$1,570,086.00View SEC Filing  
2/13/2015Loretta V CangialosiVPSell104,000$34.73$3,611,920.00View SEC Filing  
2/12/2015Anthony J MaddalunaEVPSell9,000$34.85$313,650.00View SEC Filing  
2/11/2015Frank A DamelioEVPSell14,800$34.30$507,640.00View SEC Filing  
2/10/2015Anthony J MaddalunaEVPSell9,000$33.78$304,020.00View SEC Filing  
12/8/2014Anthony J MaddalunaEVPSell6,500$32.00$208,000.00View SEC Filing  
11/10/2014Charles H HillEVPSell8,285$30.18$250,041.30View SEC Filing  
11/7/2014John D YoungInsiderSell21,600$29.89$645,624.00View SEC Filing  
10/29/2014Anthony J MaddalunaEVPSell2,425$29.56$71,683.00View SEC Filing  
6/12/2014Laurie J OlsonEVPSell36,275$29.53$1,071,200.75View SEC Filing  
6/2/2014Geno J GermanoInsiderSell30,000$29.68$890,400.00View SEC Filing  
3/17/2014John YoungInsiderSell9,000$31.38$282,420.00View SEC Filing  
3/4/2014Loretta CangialosiVPSell102,943$32.05$3,299,323.15View SEC Filing  
3/4/2014Mikael DolstenInsiderSell35,789$32.58$1,166,005.62View SEC Filing  
3/4/2014Sally SusmanEVPSell67,585$32.59$2,202,595.15View SEC Filing  
1/13/2014Frank DamelioEVPSell131,810$30.82$4,062,384.20View SEC Filing  
11/1/2013Anthony J MaddalunaEVPSell43,500$31.02$1,349,370.00View SEC Filing  
11/1/2013Loretta V CangialosiVPSell10,000$31.20$312,000.00View SEC Filing  
10/28/2013Ian C ReadCEOSell338,000$30.57$10,332,660.00View SEC Filing  
9/16/2013Freda Lewis-HallEVPSell38,461$28.70$1,103,830.70View SEC Filing  
7/31/2013Charles H HillEVPSell96,500$29.64$2,860,260.00View SEC Filing  
7/31/2013Loretta V CangialosiVPSell14,688$29.63$435,205.44View SEC Filing  
5/15/2013Amy W SchulmanEVPSell70,000$29.36$2,055,200.00View SEC Filing  
5/15/2013Ian C ReadCEOSell69,900$29.39$2,054,361.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Pfizer (NYSE:PFE)
News IconAverage True Range of Pfizer, Inc. (PFE) stands at0.41 - The Newburgh Press (NYSE:PFE) - October 26 at 6:47 PM logoStocks Buzz: Graphic Packaging Holding Company (GPK) Pfizer Inc. (PFE) Kinder Morgan, Inc. (KMI) - iStreetWire (NYSE:PFE) - October 26 at 6:47 PM logoHow Do Pfizer’s Valuation Multiples Compare with Those of Other Oncology Players in 2016? (NYSE:PFE) - October 26 at 6:47 PM logoShort Sellers Grow More Selective on Major Pharma Stocks (NYSE:PFE) - October 26 at 10:11 AM logoPfizer Becomes #20 Most Shorted Dow Stock, Replacing McDonald's (NYSE:PFE) - October 26 at 10:11 AM logoEnbrel Facing Competition from Biosimilar Versions of the Drug (NYSE:PFE) - October 26 at 10:11 AM logoEx-Oppenheimer adviser to plead guilty in U.S. to insider trading (NYSE:PFE) - October 25 at 6:47 PM logoEx-Oppenheimer adviser pleads guilty to U.S. insider trading charges (NYSE:PFE) - October 25 at 6:47 PM
News IconTop Gainers of the Day: Pfizer Inc. (NYSE:PFE) from Drug Manufacturers – Major (NYSE:PFE) - October 25 at 11:55 AM logoBristol-Myers Squibb’s 3Q16 Earnings: What’s Expected (NYSE:PFE) - October 25 at 11:55 AM logoPfizer Declines Overdone (NYSE:PFE) - October 24 at 12:16 PM logoTreating Epilepsy Is One of Pfizer’s Solid Growth Prospects (NYSE:PFE) - October 24 at 12:16 PM logoHealthcare ETFs: Gain or Pain Ahead in Q3 Earnings? (NYSE:PFE) - October 24 at 12:16 PM logoEliquis Proving to Be a Major Growth Driver for Pfizer This Year (NYSE:PFE) - October 24 at 12:16 PM logoAriad Could Follow Gilead's — Or Mylan's — Route In Drug Price Battle (NYSE:PFE) - October 24 at 12:16 PM logoThe Biggest Mergers & Acquisitions In The U.S. (NYSE:PFE) - October 23 at 10:58 AM
News IconLeerink Swann Weighs in on Pfizer Inc.'s Q3 2016 Earnings (PFE) (NYSE:PFE) - October 22 at 10:45 AM
News IconSunTrust Banks Weighs in on Pfizer Inc.'s Q3 2016 Earnings (PFE) (NYSE:PFE) - October 22 at 10:45 AM
News IconPurchases 104157 Shares of Pfizer Inc. (PFE) (NYSE:PFE) - October 22 at 10:45 AM
News IconDynamic Equity on Most Active Friday Stocks List: Pfizer Inc. (NYSE:PFE) (NYSE:PFE) - October 21 at 6:46 PM
News IconPfizer Inc. (NYSE:PFE) from Drug Manufacturers – Major – Todays Top Gains (NYSE:PFE) - October 21 at 6:46 PM logoPfizer's Medivation Receives FDA Approval For Prostate Cancer Drug XTANDI (NYSE:PFE) - October 21 at 5:24 PM logoAdvent, Bain gain edge in bid for Pfizer's Brazil venture -sources (NYSE:PFE) - October 21 at 11:00 AM logoAdvent, Bain gain edge in bid for Pfizer's Brazil venture - sources (NYSE:PFE) - October 21 at 10:15 AM
News IconPfizer Inc. (NYSE:PFE) & Tesla Motors Inc (NASDAQ:TSLA) Traders Alert - Money News (NYSE:PFE) - October 20 at 7:02 PM
News IconOwnership Change Worth Mentioning: Pfizer INC (PFE) Market ... - Chester News (NYSE:PFE) - October 20 at 7:02 PM logoBetter Buy: Pfizer Inc. vs. GlaxoSmithKline plc (NYSE:PFE) - October 20 at 9:16 AM
News IconCDC Advisory Committee on Immunization Practices Votes to Recommend New Dosing Schedule for Vaccination with TRUMENBA® (Meni... (NYSE:PFE) - October 20 at 8:05 AM logoPfizer Awarded Grant to Evaluate Vaccine to Protect Newborns Against Group B Streptococcus Infection (NYSE:PFE) - October 20 at 8:05 AM
News IconDrug Manufacturers – Major: Pfizer Inc. (NYSE:PFE) Position of the day (NYSE:PFE) - October 20 at 8:05 AM logo6:03 pm Pfizer confirms CDC Advisory Committee on Immunization Practices votes to recommend new dosing schedule for vaccination with TRUMENBA (NYSE:PFE) - October 20 at 8:05 AM logoCDC Advisory Committee on Immunization Practices Votes to Recommend New Dosing Schedule for Vaccination with TRUMENBA® (Meningococcal Group B Vaccine) (NYSE:PFE) - October 20 at 8:05 AM logoDebiopharm International SA Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer in Cancer Immunotherapy (NYSE:PFE) - October 20 at 8:05 AM logoPfizer Inc. Ready to Launch Remicade Biosimilar - TCC (NYSE:PFE) - October 19 at 3:18 PM logoPfizer to start shipping biosimilar version of J&J's Remicade in November (NYSE:PFE) - October 18 at 6:39 PM logoPfizer walks away from $118 billion AstraZeneca takeover fight (NYSE:PFE) - October 18 at 1:22 PM
News IconUpdate on Pfizer Inc. (NYSE:PFE) for the day (NYSE:PFE) - October 18 at 12:01 PM logoPfizer to Launch Remicade Biosimilar in U.S. in November (NYSE:PFE) - October 18 at 12:01 PM logoPfizer Inc. (PFE) Ready to Launch Remicade Biosimilar (NYSE:PFE) - October 18 at 12:01 PM logo[$$] J&J prepares for drug price war with Pfizer (NYSE:PFE) - October 18 at 12:01 PM logoWhy Johnson & Johnson is Tanking (NYSE:PFE) - October 18 at 12:01 PM logoJohnson & Johnson tops 3Q Street view but shares decline (NYSE:PFE) - October 18 at 12:01 PM logoPfizer to start shipping biosimilar version of J&J's Remicade in November - Reuters (NYSE:PFE) - October 18 at 7:19 AM
News IconPfizer Plans to Launch Remicade Biosimilar in November (NYSE:PFE) - October 17 at 6:37 PM
News IconLeading stocks in today’s market: Pfizer Inc. (NYSE:PFE) (NYSE:PFE) - October 17 at 6:37 PM logoPfizer set to start shipping Remicade biosimilar next month (NYSE:PFE) - October 17 at 6:37 PM logoPfizer Becomes Oversold (NYSE:PFE) - October 17 at 6:37 PM logoAlzheimer's Remains a Top Priority for Big Pharma (NYSE:PFE) - October 17 at 4:57 PM logoBRIEF-Pfizer says company to begin shipping Inflectra to wholesalers in late November (NYSE:PFE) - October 17 at 4:40 PM logoStocks Buzz: Kinder Morgan, Inc. (KMI) Pfizer Inc. (PFE) Regions Financial Corporation (RF) - iStreetWire (NYSE:PFE) - October 17 at 11:54 AM


Pfizer (NYSE:PFE) Chart for Thursday, October, 27, 2016

Last Updated on 10/27/2016 by Staff